Turkey: These 3 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Turkey

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Turkey: These 3 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Subscribe to access the full database, or Start Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
PANCREAZE	pancrelipase (amylase;lipase;protease)	2027-02-20
ZENPEP	pancrelipase (amylase;lipase;protease)	2027-02-20
EPIDUO	adapalene; benzoyl peroxide	2027-07-12
EPIDUO FORTE	adapalene; benzoyl peroxide	2027-07-12
WINLEVI	clascoterone	2027-08-03
VAFSEO	vadadustat	2026-06-26
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Turkey: These 3 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: Turkey Patent 201,808,840

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Turkey Patent 201,819,658

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Turkey Patent 201,819,658

EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can WINLEVI (clascoterone) generic drug versions launch?

Generic name: clascoterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Turkey Patent 201,909,129

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

When can VAFSEO (vadadustat) generic drug versions launch?

Generic name: vadadustat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2026
Generic Entry Controlled by: Turkey Patent 201,900,548

VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.

This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO

The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.